BRAF阳性NSCLC患者的靶向治疗药物主要包括BRAF抑制剂和MEK抑制剂,既往的研究发现两种靶向药物联合治疗疗效优于单药[32-34]。. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.